clinical trial · NCT05653271
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Acepodia Biotech, Inc.·phase1·completed·n = 16
B-cell LymphomaNon Hodgkin LymphomaDLBCLPrimary Mediastinal Large B Cell LymphomaMarginal Zone LymphomaFollicular LymphomaBurkitt LymphomaHigh-grade B-cell LymphomaCyclophosphamideFludarabineACE1831Obinutuzumab
brief summary
ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of CD20-expressing B-cell malignancies. The ACE1831-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, and efficacy of ACE1831 in patients with CD20-expressing Non-Hodgkin lymphoma.
started
Jan 21, 2023
primary completion
Mar 31, 2026
completion
Mar 31, 2026
last updated
Jun 30, 2026
official title
A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic Anti-CD20 Antibody-Conjugated Gamma Delta T-cell Therapy, in Adult Subjects With Relapsed/Refractory CD20-expressing B-cell Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol